FDA issues 5th blood pressure medication recall just four months into 2019
It’s only the end of April, and the U.S. Food and Drug Administration has just issued another blood pressure medication recall.
Fourty Four lots of losartan from Legacy Pharmaceutical Packaging were found to contain the cancer causing chemical nitrosamine (NMBA). In the past, NMBA has been linked to an “increased risk for bladder cancers.” This comes on the heels of NDMA being found in “several generic valsartan products” earlier this year. For its part, NDMA has been linked to an increased risk in colorectal and uterine cancers. Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research released a statement letting customers know that while “the maximum possible exposure to nitrosamines in ARB medicines appears to be small, their presence in drug products is not acceptable.” Luckily, so far, there have not been any reports of “adverse events” from those prescribed nitrosamine.
FDA recalls have been tough on the availability of valsartan, olmesartan and eprosartan. There’s not currently a shortage of losartan, however the FDA fears that if similar recalls continue at this rate there’s a chance losartan could suffer the same shortage issue as the drugs mentioned above. The FDA wants those prescribed any of the aforementioned blood pressure drugs to continue their use, don’t stop taking them, but please consult your doctor about your prescription. In the meantime, let’s hope that the month of May goes by without another blood pressure recall.
To read the full article at NBC News Health, follow this link: https://nbcnews.to/2GTzhC9